Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon

Hepatology

Volumn 30, Issue 2, 1999, Pages 562-566

  Heathcote, E Jenny L ^a,ao   James, Stephen ^b   Mullen, Kevin D ^c   Hauser, S C ^d   Rosenblate, H ^e   Albert Jr , Donald G ^f   Bailey, R ^g   Bain, V G ^h   Bala, K ⁱ   Balart, L A ^j   Bonkovsky, H ^k   Black, M ^l   Cassidy, W M ^m   Donovan, J ⁿ   Ehrinpreis, M ^o   Everson, G T ^p   Feinman, S V ^q   Foust, R T ^r   Fromm, H ^s   Hoefs, J C ^t   Hollinger, E B ^u   Jensen, D M ^v   Killenberg, P G ^w   Keeffe, E B ^x   Krawitt, E L ^y   Lee, S ^z   Lee, W M ^aa   VanLeeuwen, D J ^ab   Lesesne, H R ^ac   Lyche, K D ^ad   McHutchison, J ^ae   Minuk, G Y ^af   Payne, K M ^ag   Pimstone, N R ^ah   Pockros, P J ^ae   Reddy, K R ^ai   Shafritz, D A ^aj   Smith, C I ^ak   Tong, M J ^al   Willems, B E ^am   Willis, J ^an   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MARYLAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e RUSH NORTH SHORE MEDICAL CENTER   (United States)

^f AMGEN INC   (United States)

^g Hys Centre   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ St Bernardine Liver Disease Center   (United States)

^j LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^l TEMPLE UNIVERSITY HOSPITAL   (United States)

^m LOUISIANA STATE UNIVERSITY   (United States)

ⁿ UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^o HARPER UNIVERSITY HOSPITAL   (United States)

^p UNIVERSITY OF COLORADO   (United States)

^q MOUNT SINAI HOSPITAL   (Canada)

^r MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^s GEORGE WASHINGTON UNIVERSITY   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u BAYLOR COLLEGE OF MEDICINE   (United States)

^v RUSH UNIVERSITY MEDICAL CENTER   (United States)

^w DUKE UNIVERSITY   (United States)

^x STANFORD UNIVERSITY   (United States)

^y UNIVERSITY OF VERMONT   (United States)

^z UNIVERSITY OF CALGARY   (Canada)

^aa UNIVERSITY OF TEXAS AT DALLAS   (United States)

^ab UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^ac General Clinical Research Center   (United States)

^ad UNIVERSITY OF CALIFORNIA   (United States)

^ae SCRIPPS CLINIC   (United States)

^af UNIVERSITY OF MANITOBA   (Canada)

^ag UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^ah UNIVERSITY OF CALIFORNIA   (United States)

^ai UNIVERSITY OF MIAMI   (United States)

^aj ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^ak Center for MR Research   (United States)

^al HUNTINGTON MEMORIAL HOSPITAL   (United States)

^am UNIVERSITY OF MONTREAL   (Canada)

^an WASHINGTON UNIVERSITY   (United States)

^ao TORONTO WESTERN HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; CONSENSUS INTERFERON; NEUTRALIZING ANTIBODY; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERON TYPE I, RECOMBINANT; RNA, VIRAL;

EID: 20644455767     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300202     Document Type: Article

References (16)

1. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995;15:82-91.
2. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992;15:1013-1016.
3. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, Di Napoli A, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of Interferon alpha 2b. Hepatology 1993;18:1300-1305.
4. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment on chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995;332:1457-1462.
5. Antonelli G, Giannelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F, Pistello M, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha 2 therapy. Clin Exp Immunol 1996;104:384-387.
6. Hanley JP, Jarvis LM, Simmonds P, Ludlam CA. Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in haemophiliacs. Br J Haematol 1996;94:551-556.
7. Negro F, Baldi M, Mondardini A, Leandro G, Chaneac M, Manzini P, Abate ML, et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994;107:479-485.
8. Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 1995;21:645-649.
9. Bellati G, Colloredo G, Roffi L, D'Aquino M, Bonino F, Ideo G. Prevalence of breakthrough in chronic hepatitis C patients undergoing antiviral therapy: role of type and schedule of alpha interferon C.H.S.G. [Letter]. J Hepatol 1997;26:449-450.
10. Bonino F, Baldi M, Negro F, Oliveri F, Colombatto P, Bellati G, Brunetto MR. Clinical relevance of anti-interferon antibodies in the serum of chronic hepatitis C patients treated with interferon-alpha. J Interferon Cytokine Res 1997;17(Suppl 1):S35-S38.
11. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs CJ, Keeffe EB, Hollinger FB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997;26:747-754.
12. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997;26:1640-1645.
13. Familletti PC, Rubinstein S, and Pestka S. A convenient and rapid cytopathic effect inhibition assay for interferon. Methods Enzymol 1981;78:387-394.
14. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DJ, et al. Retreatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-1143.'
15. Lebovics E, Lantin J, Chaurushia G, Dworkin BM, Casellas A, Rosenthal VS. The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome. Am J Gastroenterol 1995;90:951-954.
16. Garcia-Buey L, Garcia-Monzon C, Rodriquez S, Borque MJ, GarciaSanchez A, Iglesias R, DeCastro M, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108:1770-1777.